Centre for Policy on Ageing
 

 
Do extrapyramidal features in Alzheimer patients treated with acetylcholinesterase inhibitors predict disease progression?
Author(s)H Brodaty, P Sachdev, K Berman
Journal titleAging & Mental Health, vol 11, no 4, July 2007
PublisherTaylor & Francis, July 2007
Pagespp 451-456
Sourcehttp://www.tandfonline.com
KeywordsDementia ; Behaviour disorders ; Drugs ; Longitudinal surveys ; Manchester ; Australia.
AnnotationThe longitudinal course of patients with Alzheimer's disease (AD) with and without extrapyramidal signs (EPS) taking donepezil. A cohort of 106 community-dwelling patients with probable AD receiving donepezil in Sydney, Australia (n=52) and Manchester, UK (n=54) was followed over 12 months. Cognition was measured by the Mini Mental State Examination (MMSE) and the Alzheimer's Disease Assessment Scale - Cognitive Test (ADAS-Cog) and function by the Alzheimer's Disease Cooperative Study - Activities of Daily Living Scale (ADCS-ADL). A further follow-up at 5 years examined mortality and institutionalisation. At baseline, EPS was correlated with MMSE (r=0.467), ADAS-Cog (r=0.485) and ADCS-ADL (r=0.526) scores. Patients with EPS had lower MMSE and ADCS-ADL scores than patients without EPS. Over one year, no time main effects or time x group interactions were observed for either dependent variable. At 5 years, patients with EPS were found to have a hazard of institutionalisation or death 2.2 times higher than those without EPS. There was a a positive association between EPS and cognitive and functional impairment. However, EPS did not predict more rapid cognitive or functional decline of patients taking donepezil or response to donepezil. The presence of EPS was a risk factor both for institutionalisation and for death. (RH).
Accession NumberCPA-081124226 A
ClassmarkEA: EP: LLD: 3J: 83E: 7YA

Data © Centre for Policy on Ageing
...from the Ageinfo database published by Centre for Policy on Ageing.
 
CPA home >> Ageinfo Database >> Queries to: webmaster@cpa.org.uk